Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIO phase 3 trial of oral ibrexafungerp versus oral fluconazole after IV echinocandin for candidemia or invasive candidiasis
MOH_2022-08-17_011967Phase 3Not yet recruiting
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibrexafungerp, fluconazole, caspofungin, micafungin and anidulafungin in candidemia and invasive candidiasis (2 arms), sponsored by SCYNEXIS, Inc. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
ibrexafungerpfluconazolecaspofunginmicafunginanidulafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on MOH_2022-08-17_011967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-17_011967.